You searched for: pharmacokinetics (Portugisiska - Engelska)

== pharmacokinetics ==nitrazepam is largely bound to plasma proteins.
==pharmacokinetics==nitrazepam is largely bound to plasma proteins.

- note for guidance on the evaluation on the pharmacokinetics of medicinal products in patients with
with regard to the chance of suicide, in particular at the beginning of treatment, only a limited number of remeron orodispersible tablets should be given to the patient.

concept paper on the development of a cpmp note for guidance on the clinical pharmacokinetic investigation of the pharmacokinetics of peptides and proteins.
document title

concept paper on the development of a cpmp note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal failure.
concept paper on the development of a cpmp note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal failure

gibaldi m., perrier d., (1982), pharmacokinetics, 2.a edição. marcel dekker, inc., new york.
gibaldi m and perrier d, (1982), pharmacokinetics, 2nd edition, marcel dekker, inc., new york.

adjustment for baseline covariates points to consider on the use of statistical methods for flexible design and analysis of confirmatory clinical trials points to consider on clinical pharmacokinetic investigation of the pharmacokinetics of peptides and proteins note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function points to consider on the evaluation of the pharmacokinetics of medicinal products in the paediatric population note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with hepatic impairment note for guidance on clinical investigation of medicinal products for the treatment of psoriasis points to consider on allergic rhino-conjuctivitis addendum to the note for guidance on modified release oral and transdermal dosage forms:
note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal functionpoints to consider on the evaluation of the pharmacokinetics of medicinal products in the paediatric population note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with hepatic impairment note for guidance on clinical investigation of medicinal products for the treatment of psoriasis points to consider on allergic rhino-conjuctivitis addendum to the note for guidance on modified release oral and transdermal dosage forms: